相关实验视频

Updated: Jan 11, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

使用新型化合物8e,确定EEF1A2作为骨髓瘤的潜在治疗点

Jian Xue¹, Meng Li², Ying Wang¹

¹Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China.

European journal of medicinal chemistry

|November 18, 2025

概括

研究人员确定了一种新的潜在药物标,即细胞延长因子1α2 (EEF1A2),用于骨髓瘤 (OS). 一种新的小分子,8e通过准EEF1A2.2,有效地抑制了OS细胞的增殖和瘤的生长.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

骨肉瘤 (OS) 是一种罕见的儿科癌症,死亡率高,治疗进展有限.
几十年来,缺乏明确的病原和治疗点,阻碍了OS治疗的进展.
开发新的药物标对于改善OS治疗至关重要.

研究的目的:

确定骨髓瘤 (OS) 的新型治疗点.
评估新合成的小分子 (8e) 对OS的疗效.
阐明作用机制并验证已识别的目标.

主要方法:

构建一个共价小分子库和表型选.
基于活动的蛋白质分析 (ABPP) 使用化合物9a来识别蛋白质标.
使用拉下测试,CETSA,质谱和分子对接来验证目标.
在OS细胞和异种移植模型中的体外和体外功能研究.

主要成果:

小分子8e证明了强大的OS 143B细胞增殖抑制 (IC50 = 0.73μM).
化合物8e在异种移植模型中表现出显著的抗瘤作用 (30.1%的抑制) 与低毒性.
核细胞延长因子1α2 (EEF1A2) 被确定为化合物8e的潜在标.
通过8e抑制EEF1A2抑制了AKT信号通路,导致OS细胞亡.

结论:

EEF1A2是骨髓瘤的一个有前途的治疗点.
小分子8e通过抑制EEF1A2.2,显示出作为OS新型治疗剂的潜力.
针对EEF1A2提供了一个新的策略,用于开发有效的骨髓瘤疗法.

关键词:

这是ABPPPP ABPPPP.协价分子的图书馆分子图书馆.EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1A2EEF1EEF1EEF1EEF1EEF1EEF1EEF2EEF1EEF1EEF1EEF1EEF2EEF1EEF1EEF1EEF1EEF1E2EEF1E2EEF1E1E1E2E1EF1E1E2E2E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1E1 骨质肉瘤骨质肉瘤是什么目标识别目标识别

更多相关视频

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...